Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
US stocks were expected to head in different directions on Thursday morning, as oil prices retreat but tech earnings overnight disappointed investors. Dow Jones futures were called 0.8% higher, but the S&P 500 was off 0.4% and Nasdaq futures were down 1.3%. The latter pair were...
CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available as an Ebola treatment to address the widening outbreak in the Democratic Republic of Congo, a senior executive told Reuters. The outbreak, which has so far infected a suspected 1,100 people and resulted in 42 deaths, involves a rare strain of the virus called Bundibugyo for which there are no approved vaccines or treatments.
Stock Market Today: The Dow Jones index rose Monday amid ongoing hopes for a U.S.-Iran deal. Nvidia stock jumped on a new chip.
By Twesha Dikshit, Avinash P and Johann M Cherian May 13 (Reuters) - European shares ended higher on Wednesday, led by gains in mining stocks, though caution lingered as investors weighed the economic
Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai
Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut